Drug Trial Radar · NCT00887224
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
Last checked: Nov 19, 2026Latest source record: Nov 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
874
Actual
Start
Jun 2009
Primary completion
Mar 2011
Study completion Mar 2011
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 23, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to compare the long-term efficacy and safety of desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive Disorder, using a randomized withdrawal design. Randomized withdrawal means that after receiving desvenlafaxine succinate sustained release for a predetermined period of time, subjects will be selected by chance to either continue receiving the study drug or to be withdrawn from the study drug and receive placebo for the remainder of their participation in the trial. Subjects will not know to which group they have been assigned. The study consists of an up to 14-day screening period followed by an 8-week open-label period in which subjects will knowingly receive 50 mg/day of desvenlafaxine succinate sustained release. Subjects who do not respond to treatment, demonstrating no significant change in their depressive symptoms, will be withdrawn from participation at the end of this period. Responding subjects will receive an additional 3 months of open-label desvenlafaxine succinate sustained release at the same dose. Subjects with stable response to treatment at the conclusion of this 3 month period will be randomized to either desvenlafaxine succinate sustained release at 50 mg/day or placebo in a blinded manner for an additional 6 months or until symptoms of depression return. Following discontinuation at any point after enrollment in the study, subjects will receive two weeks of follow-up monitoring, including one week of blinded taper with 25 mg/day of desvenlafaxine succinate sustained release treatment for any subjects who have been taking desvenlafaxine succinate sustained release prior to discontinuation. Subjects assigned to placebo will receive a blinded placebo taper. Following taper, subjects will be evaluated for one additional week to monitor safety.
Conditions
- Major Depressive Disorder
Interventions
Desvenlafaxine succinate sustained release 50 mgDrug
50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
Desvenlafaxine succinate sustained release 25 mgDrug
25 mg tablet for taper, once daily for 1 week
PlaceboDrug
Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185Time frame: Double-blind phase Baseline (Study Day 140) up to DB Day 185 (Study Day 325)
Locations
90 sites in 14 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Beverly Hills, California
Pfizer Investigational Site
Encino, California
Pfizer Investigational Site
Los Alamitos, California
Pfizer Investigational Site
Orange, California
Pfizer Investigational Site
Upland, California
Pfizer Investigational Site
Aurora, Colorado
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
South Miami, Florida
Pfizer Investigational Site
St. Petersburg, Florida
Pfizer Investigational Site
St. Petersburg, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Smyrna, Georgia
Pfizer Investigational Site
Hoffman Estates, Illinois
Pfizer Investigational Site
Rockville, Maryland
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
Rochester, New York
Pfizer Investigational Site
Dayton, Ohio
Pfizer Investigational Site
Portland, Oregon
Pfizer Investigational Site
San Antonio, Texas
Pfizer Investigational Site
Seattle, Washington
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Medicine Hat, Alberta, Canada
Pfizer Investigational Site
Kelowna, British Columbia, Canada
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Bathurst, New Brunswick, Canada
Pfizer Investigational Site
Burlington, Ontario, Canada
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Gatineau, Quebec, Canada
Pfizer Investigational Site
Pointe-Claire, Quebec, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
Santiago, Chile, Chile
Pfizer Investigational Site
Santiago, Chile, Chile
Pfizer Investigational Site
Santiago, Chile, Chile
Pfizer Investigational Site
Medellín, Antioquia, Colombia
Pfizer Investigational Site
Barranquilla, Atlántico, Colombia
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Bucamaranga, Santander Department, Colombia
Pfizer Investigational Site
Rijeka, Croatia
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.